NRG Principal Investigators and Research Associates are cordially invited to a workshop to discuss

**NRG-LU003: A Biomarker-Driven Protocol for Previously Treated ALK-Positive NSCLC Patients: The NCI-NRG ALK Master Protocol**

Date: Friday, July 13, 2018
Start and End Time: 11:30am – 1pm EST

Learning Objectives:
Following this activity, participants will be better able to:

1. Discuss the significance of the study.
2. Apply standards and procedures required to participate in the trial.
3. Discuss the requirements for pathology review.
4. Overview of statistical design and treatment assignment.

**Agenda**
Welcome and Introductions – Erica Field, NRG Oncology

Background to Non-Small Cell Lung Cancer Trials – Jeff Bradley, MD, NRG Oncology Lung Cancer Committee Chair

Protocol Overview – Shakun Malik, MD, NRG-LU003 Co-Chair

Blood Assay and Tissue Analysis – Jennifer Webster, Foundation of Medicine

Statistical Design – Chen Hu, PhD, Statistician, NRG Oncology

Question and Answer Session